In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.45% at $3.41. This move lagged the S&P 500's daily gain of 0.29%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.89%.
The stock of biotechnology company has risen by 11.25% in the past month, leading the Medical sector's gain of 0.32% and the S&P 500's gain of 10.54%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 6, 2026. The company is predicted to post an EPS of -$0.27, indicating a 46% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $20.73 million, up 40.65% from the year-ago period.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $90.52 million. These results would represent year-over-year changes of +35.42% and +21.21%, respectively.
Investors might also notice recent changes to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).